Press Release:
Topics:

Accelrys To Introduce Materials Studio For Intel Itanium 2-Based HP Servers

Agreement Expands Existing Relationship In Materials Science

Accelrys Inc., a wholly owned subsidiary of Pharmacopeia, Inc. (Nasdaq: PCOP), and HP (NYSE: HPQ) today announced that DMol3 and CASTEP, Accelrys' state-of-the-art quantum codes in Materials Studio(TM) 2.2, will be available on Itanium® 2-based HP servers in October 2002. Accelrys intends to port the remaining Materials Studio server codes in 2003 to the 4-way Itanium 2-based HP Server rx5670 and dual Itanium 2-based HP Server rx2600 systems running Red Hat Linux 7.2.

"The fact that Materials Studio now will be available on HP's Itanium 2-based platform underlines our continued commitment to enable chemical and materials research organizations to adopt the latest and best performing hardware platforms available," said John S. Delli-Santi, vice president and general manager, Materials Science. "This significant development couples state-of-the-art software with state-of-the-art hardware, a powerful combination to push forward the boundaries of chemical research and development."

HP's Itanium 2-based servers, enabled by the HP Chipset zx1, deliver record-breaking performance that will address the most computationally and data-intensive scientific projects of Materials Studio customers utilizing applications such as DMol3 and CASTEP, and at a better price / performance than comparable RISC platforms. Invented by HP, the HP Chipset zx1 provides customers with a cost-effective, high bandwidth and low latency solution for 1- to 4-way workstations and servers.

Under the companies' current alliance, Materials Studio is available on HP AlphaServer systems running Tru64 UNIX and industry-standard HP ProLiant servers running either Windows or Linux.

"The planned introduction of Materials Studio on HP's family of Itanium 2-based servers points to exciting new possibilities in scientific computing by significantly expanding problem solving capabilities," said Steve Joachims, director of marketing and solutions for HP's High Performance Technical Computing Division.

"Today's announcement by Accelrys and HP exemplifies the benefits and momentum behind the Itanium 2 processor for high performance computing environments," said Mike Graf, marketing manager for Intel's Itanium processor family. "Accelrys' choice of operating systems coupled with the high performance and cost effectiveness of these systems reflect the value Itanium 2-based systems provide in accelerating chemicals and materials research."

About Materials Studio

Materials Studio is a client-server software environment offering a comprehensive suite of tools to predict key properties and processes related to organic crystalline materials (including fine chemicals, pigments, dyes, and drugs), inorganic materials (including catalysts, metals, and ceramics), and polymeric and soft materials. The primary market for this technology is product discovery and process development in the chemicals industry. With the release of version 2.2, Materials Studio's quantum mechanical servers DMol3 and CASTEP will be supported on HP Itanium 2 based systems with Red Hat LINUX 7.2 as well as on HP AlphaServers running Tru64 UNIX V4.0F and above, HP Intel IA32 systems running Windows NT 4.0, 2000, XP, Intel IA32 RedHat LINUX 6.0 and above, and IRIX 6.5.4 and above. Materials Studio client applications are supported on Windows 98, Me, NT 4.0, 2000 and XP.

About HP

HP is a leading global provider of products, technologies, solutions and services to consumers and businesses. The company's offerings span IT infrastructure, personal computing and access devices, global services and imaging and printing. HP completed its merger transaction involving Compaq Computer Corp. on May 3, 2002. More information about HP is available at http://www.hp.com.

About Accelrys Inc. Accelrys is a leading provider of software for computation, simulation, and the management and mining of scientific data used by biologists, chemists, and materials scientists for product design, drug discovery, and development. Accelrys' platform technology and consulting services enable enterprise-wide solutions tailored to today's leading research organizations. The company's two main centers of excellence are in San Diego, and Cambridge, UK. These centers combine research and product development with facilities to support significant collaborative projects. Accelrys is a subsidiary of Pharmacopeia, Inc. (NASDAQ: PCOP) and was launched in June 2001, combining leading software companies Molecular Simulations Inc., Synopsys Scientific Systems, Oxford Molecular, GCG, and Synomics Ltd. More information on Accelrys can be found at http://www.accelrys.com.


Discovery Studio is a registered trademark of Accelrys Inc. within the United States and/or various other countries.

Intel and Itanium are trademarks or registered trademarks of Intel Corporation or its subsidiaries in the United States and other countries.


When used anywhere in this document, the words expects, believes, anticipates, estimates, and similar expressions are intended to identify forward-looking statements. Forward-looking statements herein may include statements addressing future financial and operating results of Pharmacopeia. Pharmacopeia has based these forward-looking statements on its current expectations about future events. Such statements are subject to risks and uncertainties including, but not limited to, the successful implementation of Pharmacopeia's strategic plans, the acceptance of new products, the obsolescence of existing products, the resolution of existing and potential future patent issues, additional competition, changes in economic conditions, and other risks described in documents Pharmacopeia has filed with the Securities and Exchange Commission, including its most recent report on Form 10-K and subsequent reports on Form 10-Q. All forward-looking statements in this document are qualified entirely by the cautionary statements included in this document and such filings. These risks and uncertainties could cause actual results to differ materially from results expressed or implied by forward-looking statements contained in this document. These forward-looking statements speak only as of the date of this document. Pharmacopeia disclaims any undertaking to publicly update or revise any forward-looking statements contained herein to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.

About HP

HP Inc. creates technology that makes life better for everyone, everywhere. Through our portfolio of printers, PCs, mobile devices, solutions, and services, we engineer experiences that amaze. More information about HP Inc. is available at http://www.hp.com.